TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06340763

Intervention type: DEVICE
Intervention: JETi Hydrodynamic Thrombectomy System
Description: The JETi Hydrodynamic Thrombectomy System is a hydro-mechanical aspiration system intended for the removal of intravascular thrombus. The system is comprised of the JETi Catheter, JETi Pump Set, and JETi Saline Drive Unit (SDU), accessory cart, suction tubing, and non-sterile canister set. The JETi System is designed to simultaneously deliver a stream of high-pressure saline via a displacement pump to the distal tip of the JETi Catheter, while aspirating thrombotic material macerated by the saline stream.
Study: NCT05008705

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Patients will receive diary 2 doses of the protein supplement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation.
Description: Patients will receive diary sessions of neuromuscular electrostimulation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (isocaloric supplement)
Description: Patients will receive diary 2 doses of the isocaloric supplement

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham for neuromuscular electrostimulation.
Description: Patients will not receive neuromuscular electrostimulation.
Study: NCT04759482

Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: Polysomnography consisted in recording sleep parameters during one night, using a non-invasive multi-channels device, including respiratory sensors, electrocardiogram and electroencephalogram
Study: NCT04727840

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Zirconium Cyclosilicate Oral Product
Description: Sodium zirconium cyclosilicate (SZC), a non-absorbed cation exchanger, selectively binds potassium in the intestine. SZC is in a powder form and will be provided to patients in packets containing 5g or 10gm of the medication. Participants will mix the contents of one packet with water (about 45mL). The drink should be stirred and drank immediately. If powder remains in the glass, then water should be added and the remainder of the drink should be consumed. Other medications should be taken 2 hours before or after SZC.~At Day 0 and Day 1, participants will be taking SZC at 10gm three times a day. A serum potassium will be checked on Day 2; if serum potassium is \<5.1mEq/L, then the dose will be decreased to the maintenance dose of 5gm per day. At each serum potassium checks, the medication dosage will be adjusted accordingly.
Study: NCT05324579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral testing during neuronal recordings
Description: Participants undergoing clinically planned neurosurgical procedures will undergo single-neuronal recordings as they perform brief behavioral tasks.
Study: NCT05488054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients will undergo physical therapy following surgical intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monitored Work-out
Description: Healthy volunteers will undergo a monitored workout for comparison of data

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxy Oxygen Sensor Device
Description: Individuals will wear a Moxy sensor device during workouts to monitor oxygen and hemoglobin levels in their muscles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxy Oxygen Sensor Device
Description: Individuals will wear a Moxy sensor device during workouts to monitor oxygen and hemoglobin levels in their muscles
Study: NCT05881798

Intervention type: DEVICE
Intervention: Celect Platinum Vena Cava Filter
Description: Inferior vena cava filter
Study: NCT06531538

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG4
Description: Multivalent pneumococcal conjugate vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG4
Description: Multivalent pneumococcal conjugate vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20-valent pneumococcal conjugate vaccine (20vPnC)
Description: 20-valent pneumococcal conjugate vaccine (20vPnC)
Study: NCT04870944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACT Complex-targeting Curaxin CBL0137
Description: Given IV
Study: NCT05919940

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: additional substitution of protein
Description: Day one (admission) no nutrition is applied.~Protein target is increased as follows:~* to a level of 1,2g/kg/d on day 1 after ICU admission~* to a level of 1,4g/kg/d on day 2 after ICU admission~* to a level of 1,6g/kg/d on day 3 after ICU admission~* to a level of 1,8g/kg/d on day 4 after ICU admission~* to a level of 2,0g/kg/d from day 5 onwoards~Additional protein is given within 2 hours after mobilization respectively:~* to 0,125g/kg/d on day 1 after ICU admission~* to 0,2g/kg/d on day 2 after ICU admission~* to 0,25g/kg/d on day 3 after ICU admission~* to 0,3g/kg/d from day 4 after ICU admission onwoards

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: twice daily 60 minutes till day 28 or ICU discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge
Study: NCT05942716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of a PET radiotracer
Description: A highly selective 5-HT2A receptor ligand (\[18F\]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine.~Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic.
Study: NCT04275999

Intervention type: DRUG
Group type: OTHER
Intervention: ivermectin
Description: Subjects will be given the ivermectin with an electronic monitoring device attached with a return appointment at month 3 for end of study visit. Subjects will be instructed to use the ivermectin once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: Subjects will be given the ivermectin with an electronic monitoring device attached with a return appointment at month 3 for end of study visit. Subjects will be instructed to use the ivermectin once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: Subjects will be given the ivermectin with an electronic monitoring device attached with a return appointment at month 3 for end of study visit. Subjects will be instructed to use the ivermectin once daily.
Study: NCT06205472

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant SIB radiotherapy
Description: Eligibility patients will receive IMRT or VMAT to high risk area of tumor bed and tumor bed. The prescription dose to 95% GTVtb boost was planned at 55-60Gy, with PTV 45-50Gy, in 23-25 fractions,mainly depending on the dose constraints of OARs.
Study: NCT05965531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: TAS-102 is given in a dose of 35 mg/m2, twice daily on the 1st to 5th and 8th to 12th days of the period of neoadjuvant radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: intensity-modulated radiotherapy
Study: NCT04275999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital interaction
Description: Subjects will receive weekly digital interaction; an electronic survey asking about their use of the ivermectin which will have the electronic monitoring device attached. Subjects will be instructed to use the ivermectin once daily. They will have a 3 month return appointment for end of study visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GPSkin
Description: Subjects in the GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin with the electronic monitoring device once daily. They will be scheduled for a 3 month end of study visit.
Study: NCT06112301

Intervention type: DIAGNOSTIC_TEST
Intervention: IdentiClone Dx IGH (IC IGH Dx) Assay
Description: The IdentiClone Dx IGH Assay is an in vitro diagnostic product intended for qualitative, capillary electrophoresis based-detection of clonality in immunoglobulin heavy chain gene rearrangements (IGH) in peripheral blood specimens as an adjunctive method for the diagnosis of B-cell lymphoproliferative disease

Intervention type: DIAGNOSTIC_TEST
Intervention: IdentiClone Dx IGH (IC IGH Dx) Assay
Description: The IdentiClone Dx IGH Assay is an in vitro diagnostic product intended for qualitative, capillary electrophoresis based-detection of clonality in immunoglobulin heavy chain gene rearrangements (IGH) in peripheral blood specimens as an adjunctive method for the diagnosis of B-cell lymphoproliferative disease
Study: NCT05770596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C group
Description: patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: patients in this group will receive placebo tablets with the same manner; orally 1 hour before surgery and for 50 days starting from the 2nd postoperative day.
Study: NCT06539754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants will have bone conducting headphones available to listen to the music of their choice from premade Spotify playlists.
Study: NCT06506110

Intervention type: OTHER
Intervention: Retrieving of retrospective data from Epic
Description: Retrospective data from Epic will be extracted to determine the Patient Acceptable Symptom State (PASS) for the numeric rating scale (NRS) pain score in the first 48 hours after surgery in patients who received intravenous Patient Controlled Analgesia.
Study: NCT05344027

Intervention type: DRUG
Intervention: Mitotane
Description: Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
Study: NCT05451472

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: thyroid function tests
Description: Thyroid function tests:thyroid stimulating hormone (TSH), total thyroxine (T4), free thyroxine (FT4), total triiodothyronine (T3), and free triiodothyronine (FT3)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: complete blood count
Description: complete blood count

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum creatinine
Description: serum creatinine

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood urea
Description: blood urea

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum electrolyte
Description: serum electrolyte

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum calcium
Description: serum calcium

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum phosphorus
Description: serum phosphorus

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: parathyroid hormone level
Description: parathyroid hormone level

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: liver function test
Description: ALT_AST_Total biliruin_total protein _serum albumin

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: arterial blood gases
Description: PH_PCO2_PO2_HCO3_base deficit

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: complete urine analysis
Description: complete urine analysis
Study: NCT05000372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-grazytracer
Description: 68Ga-grazytracer PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Biograph mCT Flow 64 scanner or Total-body PET/CT uEXPLORER scanner will be applied, and the scan range will be from the top of the head to 1/3 of the upper thigh.
Study: NCT06438198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-specified switch from controlled to assisted ventilation when PaO2/FiO2-ratio > 200 mmHg
Description: A pre-specified switch from controlled to assisted ventilation will be initiated when PaO2/FiO2-ratio \> 200 mmHg. The moment of switch is pre-specified but patient management and ventilator settings are up to the clinical team. Switch is complete when the patient triggers all breaths spontaneously. Switch success is defined if patient reaches 72 hours on assisted ventilation. Switch failure is defined if patient switches back to controlled ventilation for more than 2 hours before 72 hours.
Study: NCT05320406

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Given IM or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO
Study: NCT05198258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation strategy - experimental group
Description: On-line theoretical education and three hours of practical training by the project leaders. Contact with the project team via e-mail, phone and on-line repetition of the education for remaining of the clinical examination, neck-specific program and the progression of exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation - control group
Description: Physiotherapists in the control group will receive the same theoretical and practical training as the experimental group but without repetition of the education or support from the research team.
Study: NCT05973578

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic radiotherapy
Description: Single-session high dose stereotactic radiotherapy
Study: NCT04758858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketone journal
Description: During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adherence to the diet (Keenoa)
Description: During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adherence to the diet (Keenoa)
Description: During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adherence to the diet (Keenoa)
Description: During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
Study: NCT06358521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led primary care model for hip and knee pain
Description: 1. Initial assessment and screening: The PT will provide a comprehensive assessment according to established clinical practice guidelines.~2. Brief individualized intervention at first visit: The PT intervention will be at the discretion of the PT to reflect real-world PT intervention.~3. Health services navigation: Participants will be provided with options available to them in their community for rehabilitation. For example, they may be referred to community PT for ongoing management. Participants will be assessed regarding the need for specialist referrals or resources available to manage complex clinical presentations. Participants may be referred to the primary care provider if no specialized services are needed or when the PT cannot provide a direct referral.~4. Additional PT care: Patients who require community PT but do not have the appropriate coverage for community-based services will be managed by the PT who provided the assessment in the primary care setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physician-led primary care model for hip and knee pain
Description: The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
Study: NCT06070337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-Guard
Description: A novel Haemodialyser primer used for one treatment only
Study: NCT06176391

Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Cord Stimulation
Description: Single lead placement in the posterior thoracic epidural space (T1-T4) connected to a subcutaneous battery
Study: NCT04964947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin Injection
Description: 80 milligrams of tobramycin diluted in 40 milliliters of normal saline
Study: NCT05580614

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: MRI (Magnetic Resonance Imaging) paired ERP/Sham YBOCs(Yale-Brown Obsessive Compulsive Scale) (4,8,12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tVNS
Description: MRI (Magnetic Resonance Imaging) paired ERP/tVNS YBOC's (Yale-Brown Obsessive Compulsive Scale) (4, 8, 12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.
Study: NCT05343988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrical Nerve Field Stimulation (PENFS) device application
Description: PENFS device will be used to treat children with paroxysmal sympathetic hyperactivity (PSH) due to acute severe brain injury.
Study: NCT06411990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fenestrated Endovascular Aneurysm Repair using the LIFE Device System
Description: Fenestrated Endovascular Aneurysm Repair
Study: NCT06158074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrical pudendal nerve stimulation
Description: The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 60 minutes targeted the pudendal nerve, thrice weekly for a total of 4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacral neuromodulation
Description: In the prone position, patients undergo sacral nerve root localization through MRI and CT fusion analysis. A 3D-printed sacral foramen puncture template is crafted for precision. Using local anesthesia, a 20G needle at a 60° angle enters the S3 sacral foramen along the template. A temporary stimulator, delivering square waves (14-35 Hz, 210-360 μs), tests motor and sensory responses to confirm accuracy. Self-fixating electrodes are then implanted, validated, and tunneled subcutaneously. External connection to a temporary stimulator provides a 4-week therapeutic experiential stimulation.
Study: NCT06457737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPS Empress Direct
Description: Resin composite will be heated and used to lute a ceramic partial coverage restoration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bisco Duo-Link Universal
Description: Dual cure adhesive resin cement will be used to lute a ceramic partial coverage restoration.
Study: NCT05125380

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VIA (Visual Inspection with Acetic acid) and VILI (Visual Inspection with Lugol's Iodine)
Description: A triage test that involved a gynaecological exam that applies acetic acid and then Lugol's iodine on the surface of the external os of the cervix.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VIA (Visual Inspection with Acetic acid)
Description: A triage test that involved a gynaecological exam that applies acetic acid on the surface of the external os of the cervix.
Study: NCT05560789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity (cycling on a stationary bicycle ergometer or walking on a treadmill)
Description: At time 0, exercise will be initiated and intensity will be increased at 2 minute intervals to achieve low intensity for 30 minutes (as defined by heart rate target 50-55% of maximum heart rate determined as 220-age). Next, intensity will be increased at 2 minute intervals until the heart rate target for moderate intensity exercise is achieved (55-65% of max heart rate), or the total duration of exercise of up to 60 minutes is achieved.
Study: NCT05033912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CST-2032, matching placebo for CST-2032, CST-107
Description: CST-2032 and matching placebo oral liquid; CST-107 white capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CST-2032, matching placebo for CST-2032, CST-107
Description: CST-2032 and matching placebo oral liquid; CST-107 white capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CST-2032, matching placebo for CST-2032, CST-107
Description: CST-2032 and matching placebo oral liquid; CST-107 white capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CST-2032, matching placebo for CST-2032, CST-107
Description: CST-2032 and matching placebo oral liquid; CST-107 white capsules